Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Rectal Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 17Fallopian Tube Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Brain Neoplasms 10Neoplasms 9Glioblastoma 9Brenner Tumor 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Oligodendroglioma 6Gliosarcoma 6Glioma 6Breast Neoplasms, Male 6Adenocarcinoma of Lung 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Astrocytoma 5Adenocarcinoma, Bronchiolo-Alveolar 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

luprolide acetate gel depot 1exemestane 1darolutamide 1X-Rays 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leuprolide 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Granulosa cell tumor of the ovary × Bevacizumab × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡